Phase 2 N=85 Safety and Benefit Study of Droxidopa to Treat Patients With Intradialytic Hypotension
Intradialytic Hypotension
Primary: Change in Average Mean Arterial Blood Pressure During Hemodialysis — -0.12; 1.95; 1.60 mmHg — p=0.693
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=211 Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
Colorectal Cancer
Primary: Objective Response Rate — 0.33; 0.38; 0.49 proportion
Phase 2 N=81 Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Fallopian Tube Cancer · Ovarian Cancer · Primary Peritoneal Cavity Cancer
Primary: Objective Tumor Response — 4; 8; 8; 32 Participants
Phase 2 N=71 Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
Fallopian Tube Cancer · Ovarian Cancer · Primary Peritoneal Cavity Cancer
Primary: Objective Tumor Response — 21; 32; 17; 1 participants
Phase 2 N=2 A Proof of Concept Study of the Safety, Tolerability, and Efficacy of Avastin (Bevacizumab) in Patients With Chemo-naive Chronic Lymphocytic Leukemia
Lymphocytic Leukemia, Chronic
Primary: Bone Marrow Response — -20.0; -20.0 Percentage of infiltration
Phase 2 N=110 A Three Day Trial of Azithromycin Plus Chloroquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria
Falciparum Malaria
Primary: Percentage of Participants With Parasite Clearance at Day 28 — 97.20 percentage of participants
Phase 2 N=90 A Study of Avastin (Bevacizumab) in Combination With Taxane-based Chemotherapy as First Line Treatment in Patients With HER-2 Negative Breast Cancer
Breast Cancer
Primary: Progression-free Survival — 11.51 Months
Phase 2 N=403 Safety and Efficacy of Once-Daily KRP-104 in Type 2 Diabetics With Inadequate Glycemic Control on Metformin Alone
Type 2 Diabetes
Primary: Change in HbA1c From Baseline (Week 0) to Week 24 — -0.09; -0.41; -0.70; -0.71 % HbA1c
Phase 2 N=153 A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer
Breast Cancer
Primary: Percentage of Participants With a Cardiac Event Within 12 Weeks After the Start of Trastuzumab Emtansine Treatment — 0 Percentage of participants
Phase 2 N=22 Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
Insular Thyroid Cancer · Recurrent Thyroid Cancer · Stage II Follicular Thyroid Cancer
Primary: Objective Tumor Response Rate Assessed by RECIST — 0 participants
Phase 2 N=40 A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab™ in Patients Undergoing an Elective Abdominal Liposuction Procedure
Sedation · Anxiety · Pain
Primary: Summed Richmond Agitation Sedation Score (RASS) Over the 4-hour Study Period (SRS-4) — -5.44; 0.79 units on a scale — p=<0.001
Phase 2 N=20 A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma
Malignant Melanoma
Primary: Percentage of Participants With Complete Response (CR) or Partial Response (PR) — 15 percentage of participants
Phase 2 N=142 Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
Leukemia · Myelodysplastic Syndromes · Myelodysplastic/Myeloproliferative Neoplasms
Primary: Number of Participants With Response — 0; 0; 3; 1 participants
Phase 2 N=74 A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma
Basal Cell Carcinoma
Primary: Percentage of Participants With Complete Histologic Clearance — 42.0; 16.0; 44.0 Percentage of participants — p=0.8463
Phase 2 N=43 Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors
High Grade Gliomas · Brain Tumors
Primary: Median Progression Free Survival. — 10.5 months